Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Assets (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Assets for 15 consecutive years, with $4.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 24.55% year-over-year to $4.6 billion, compared with a TTM value of $4.6 billion through Dec 2025, up 24.55%, and an annual FY2025 reading of $4.6 billion, up 24.55% over the prior year.
  • Assets was $4.6 billion for Q4 2025 at Neurocrine Biosciences, up from $4.3 billion in the prior quarter.
  • Across five years, Assets topped out at $4.6 billion in Q4 2025 and bottomed at $1.8 billion in Q1 2021.
  • Average Assets over 4 years is $3.2 billion, with a median of $3.3 billion recorded in 2024.
  • The sharpest move saw Assets skyrocketed 47.15% in 2024, then increased 6.2% in 2025.
  • Year by year, Assets stood at $2.0 billion in 2021, then skyrocketed by 61.18% to $3.3 billion in 2023, then rose by 14.37% to $3.7 billion in 2024, then grew by 24.55% to $4.6 billion in 2025.
  • Business Quant data shows Assets for NBIX at $4.6 billion in Q4 2025, $4.3 billion in Q3 2025, and $3.9 billion in Q2 2025.